Biotech Values

[DewDiligence]

RPRX – Because of the fact that I consider the info less material than you do…

How can the dropout rate for Proellex patients in what is probably the most important clinical trial to date be anything less than highly consequential?

and because of the fact that they seem to equally disclose to everyone who asks…

Under Reg FD, if the information is material, the onus is on the company to disclose it non-selectively in the first place. Willingness to disclose is a new standard that you and PGS have invented—it is not a defense recognized by the regulation, nor should it be for the reasons already mentioned.